Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
- PMID: 9302344
- DOI: 10.1016/s0008-6363(97)00091-6
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients
Abstract
Background: Experimental data suggest that aldosterone has harmful effects promoting myocardial fibrosis and disturbing autonomic balance. There has been no evidence of these potential effects in intact man.
Methods and results: We report the findings in 31 patients with stable chronic heart failure (CHF) who were treated with spironolactone (50-100 mg/day) or placebo in addition to diuretics and angiotensin converting enzyme (ACE) inhibition. In a controlled randomised double-blind study, we found that spironolactone treatment reduced circulating levels of procollagen type III N-terminal amino peptide, a marker of vascular collagen turnover, and in addition increased time-domain parameters of heart rate variability (n = 24). These latter parameters suggest a parasympathomimetic effect for additional spironolactone. Spironolactone significantly reduced heart rate (prolonged RR interval) particularly during the dawn hours (06.00-09.00 h). In this unbalanced study it was not possible to provide a detailed diurnal assessment of the impact of spironolactone on heart rate variability, but the preliminary data suggest that there may be an interaction with the autonomic nervous system which varies in time.
Conclusions: These are the first human data to show that use of the aldosterone antagonist, spironolactone, can positively improve time-domain heart rate variability and reduce myocardial collagen turnover, as reflected by further reductions in serum procollagen peptide, despite concurrent ACE inhibitor treatment. Residual aldosterone after ACE inhibitor treatment may therefore have a role promoting arrhythmia and cardiac death by two mechanisms. Effects of additional spironolactone on slowing heart rate (and potentially the detrimental effect of aldosterone) were most prominent between 6 a.m. and 10 a.m. when cardiac death is also known to be most prominent.
Similar articles
-
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.Hypertension. 2001 Nov;38(5):1227-32. doi: 10.1161/hy1101.099484. Hypertension. 2001. PMID: 11711528 Review.
-
A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.JACC Cardiovasc Imaging. 2011 Dec;4(12):1239-49. doi: 10.1016/j.jcmg.2011.08.014. JACC Cardiovasc Imaging. 2011. PMID: 22172779 Clinical Trial.
-
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.Am J Cardiol. 1995 Dec 15;76(17):1259-65. doi: 10.1016/s0002-9149(99)80353-1. Am J Cardiol. 1995. PMID: 7503007 Clinical Trial.
-
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.J Am Coll Cardiol. 2001 Jun 1;37(7):1800-7. doi: 10.1016/s0735-1097(01)01243-8. J Am Coll Cardiol. 2001. PMID: 11401114 Clinical Trial.
-
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].Praxis (Bern 1994). 1997 Apr 2;86(14):566-74. Praxis (Bern 1994). 1997. PMID: 9198851 Review. German.
Cited by
-
Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.Curr Hypertens Rep. 2003 Apr;5(2):122-5. doi: 10.1007/s11906-003-0068-z. Curr Hypertens Rep. 2003. PMID: 12642011 Review.
-
Autonomic effects of spironolactone and MR blockers in heart failure.Heart Fail Rev. 2005 Jan;10(1):63-9. doi: 10.1007/s10741-005-2350-4. Heart Fail Rev. 2005. PMID: 15947893 Review.
-
Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog.Pharm Res. 2000 Nov;17(11):1426-31. doi: 10.1023/a:1007597713530. Pharm Res. 2000. PMID: 11205738
-
Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.Heart. 2004 Jul;90(7):765-70. doi: 10.1136/hrt.2003.017368. Heart. 2004. PMID: 15201246 Free PMC article. Clinical Trial.
-
Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone.Pflugers Arch. 2007 Jun;454(3):403-13. doi: 10.1007/s00424-007-0211-9. Epub 2007 Jan 23. Pflugers Arch. 2007. PMID: 17242955
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous